Everolimus etkileşimleri

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions (5.2) ] . (Adalimumab etiketi, Kutulu uyarı)

• CYP3A Inhibitors: Avoid co-administration with strong CYP3A inhibitors. (Akalabrutinib etiketi, İlaç etkileşimleri)

…(Childs-Pugh categories B and C), since alfuzosin blood levels are increased in these patients [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3) ]. with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . in… (Alfuzosin etiketi, Kontrendikasyonlar)

Avoid alcohol-, hydrogen peroxide-, iodine-, or thyme- containing products, as they may exacerbate the condition. (Everolimus etiketi, Uyarılar ve önlemler)

Concomitant use of almotriptan tablets and potent CYP3A4 inhibitors should be avoided in patients with renal or hepatic impairment [see Clinical Pharmacology ( 12.3 )] . (Almotriptan etiketi, İlaç etkileşimleri)

• taking strong cytochrome P450 3A (CYP3A) inhibitors (e.g., ketoconazole, itraconazole), except ritonavir [see Dosage and Administration (2.5) , Warnings and Precautions (5.5) , Drug Interactions (7.1) ] . (Alprazolam etiketi, Kontrendikasyonlar)

If concomitant use of DYANAVEL XR with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DYANAVEL XR with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (Amfetamin etiketi, Uyarılar ve önlemler)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (Amfetamin ve dekstroamfetamin etiketi, İlaç etkileşimleri)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

For patients receiving ELIQUIS at a dose of 2.5 mg twice daily, avoid coadministration with combined P-gp and strong CYP3A4 inhibitors [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3) ] . (Apiksaban etiketi, İlaç etkileşimleri)

Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (Avanafil etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Concomitant administration of BIXLENVO with combined P-gp, UGT1A1, and strong CYP3A inhibitors is not recommended. (Biktegravir, emtrisitabin ve tenofovir alafenamid etiketi, İlaç etkileşimleri)

Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with TRACLEER is not recommended. (Bosentan etiketi, İlaç etkileşimleri)

• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (Bosutinib etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors) with CYCLOSET should be avoided. (Bromokriptin etiketi, İlaç etkileşimleri)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (Buprenorfin etiketi, İlaç etkileşimleri)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (Butalbital, aspirin, kafein ve kodein etiketi, Kutulu uyarı)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (Butalbital, parasetamol, kafein ve kodein etiketi, Kutulu uyarı)

Strong CYP3A4 inhibitors: Avoid concomitant use. (Daridoreksant etiketi, İlaç etkileşimleri)

Immunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy. (Darunavir etiketi, İlaç etkileşimleri)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib etiketi, İlaç etkileşimleri)

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (Deksametazon etiketi, İlaç etkileşimleri)

If serotonin syndrome occurs, discontinue dextroamphetamine sulfate and the CYP2D6 inhibitor [see Warnings , Overdosage ]. (Dekstroamfetamin etiketi, İlaç etkileşimleri)

QT Prolongation: Monitor ECG if concomitant use of drugs that prolong QT interval cannot be avoided or if concomitant CYP3A4 inhibitors used. (Dekstrometorfan ve kinidin etiketi, Uyarılar ve önlemler)

WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH POTENT CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. (Dihidroergotamin etiketi, Kutulu uyarı)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Avoid concomitant use of Doxorubicin Hydrochloride Injection with inhibitors of CYP3A4, CYP2D6, or P-gp. (Doksorubisin etiketi, İlaç etkileşimleri)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (Dosetaksel etiketi, İlaç etkileşimleri)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Drug-Drug Interactions Strong Inhibitors of Cytochrome P450 (CYP) 3A4 Tamsulosin-containing products, including JALYN, should not be coadministered with strong CYP3A4 inhibitors (e.g., ketoconazole) as this can significantly increase tamsulosin exposure [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ]. (Dutasterid ve tamsulosin etiketi, Uyarılar ve önlemler)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (Everolimus etiketi, Uyarılar ve önlemler)

• Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ]. (Eletriptan etiketi, Kontrendikasyonlar)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

…Patients Eplerenone is contraindicated in all patients with: • serum potassium > 5.5 mEq/L at initiation, • creatinine clearance ≤ 30 mL/min, or • concomitant administration of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir) [see Drug Interactions (7.1) , Clinical Pharmacology (12.3)… (Eplerenon etiketi, Kontrendikasyonlar)

WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (Ergotamin ve kafein etiketi, Kutulu uyarı)

Avoid co-administering erlotinib with strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) or a combined CYP3A4 and CYP1A2 inhibitor (e.g., ciprofloxacin). (Erlotinib etiketi, İlaç etkileşimleri)

Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A (see CONTRAINDICATIONS ). (Estazolam etiketi, Uyarılar)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

VYTORIN is contraindicated in the following conditions: Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) [see Drug Interactions (7.1) ] . (Ezetimib ve simvastatin etiketi, Kontrendikasyonlar)

• Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of fentanyl. (Fentanil etiketi, Kutulu uyarı)

CYP3A4 Inhibitors Doses of Toviaz greater than 4 mg are not recommended in adult patients taking strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, and clarithromycin [see Dosage and Administration (2.5) ]. (Fesoterodin etiketi, İlaç etkileşimleri)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (Fludrokortizon etiketi, Uyarılar)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (Everolimus etiketi, Uyarılar ve önlemler)

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. (Flunisolid etiketi, Önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Flutikazon etiketi, İlaç etkileşimleri)

Avoid strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): May increase risk of systemic corticosteroid and cardiovascular effects. (Flutikazon ve salmeterol etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Cytochrome P450 3A4 Interaction The concomitant use of HYSINGLA ER with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (Hidrokodon etiketi, Kutulu uyarı)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and homatropine methylbromide with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. (Hidrokodon ve homatropin etiketi, Kutulu uyarı)

Cytochrome P450 3A4 Interaction The concomitant use of Hydrocodone Bitartrate and Ibuprofen Tablets with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which may cause potentially fatal respiratory depression. (Hidrokodon ve ibuprofen etiketi, Kutulu uyarı)

Cytochrome P450 3A4 Interaction The concomitant use of Hydrocodone Polistirex and Chlorpheniramine Polistirex with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. (Hidrokodon ve klorfeniramin etiketi, Kutulu uyarı)

Cytochrome P450 3A4 Interaction The concomitant use of hydrocodone bitartrate and acetaminophen tablets with all Cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (Hidrokodon ve parasetamol etiketi, Kutulu uyarı)

• Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with CAMPTOSAR. (İrinotekan etiketi, İlaç etkileşimleri)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (Everolimus etiketi, Uyarılar ve önlemler)

…bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (İvabradin etiketi, Kontrendikasyonlar)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) while taking COMETRIQ or reduce the dosage of COMETRIQ if concomitant use with strong CYP3A4 inhibitors cannot be avoided [see Dosage and Administration ( 2.2 ), Clinical Pharmacology… (Kabozantinib etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (Everolimus etiketi, Uyarılar ve önlemler)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (Kladribin etiketi, İlaç etkileşimleri)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (Everolimus etiketi, Uyarılar ve önlemler)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (Kodein etiketi, Kutulu uyarı)

Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [see Drug Interactions (7) ] . (Kolşisin etiketi, Kontrendikasyonlar)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Strong CYP3A4 Inhibitors: Avoid coadministration of strong CYP3A4 inhibitors with VITRAKVI. (Larotrektinib etiketi, İlaç etkileşimleri)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Strong or moderate CYP3A inhibitors: Avoid concomitant use. (Lemboreksant etiketi, İlaç etkileşimleri)

If concomitant use of VYVANSE with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate VYVANSE with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome. (Lisdeksamfetamin etiketi, Uyarılar ve önlemler)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (Lomitapid etiketi, Kontrendikasyonlar)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

• Strong CYP3A Inhibitors : Avoid concomitant use; reduce LORBRENA dose if concomitant use cannot be avoided. (Lorlatinib etiketi, İlaç etkileşimleri)

Concomitant administration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone and cobicistat-containing products) (see WARNINGS , Myopathy/Rhabdomyolysis ). (Lovastatin etiketi, Kontrendikasyonlar)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions ( 7.1 )]. (Lurasidon etiketi, Kontrendikasyonlar)

SELZENTRY is contraindicated in patients with severe renal impairment or ESRD (creatinine clearance [CrCl] less than 30 mL per minute) who are concomitantly taking potent CYP3A inhibitors or inducers [see Warnings and Precautions ( 5.3 )]. (Maravirok etiketi, Kontrendikasyonlar)

Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.2 , 12.3 ) . (Masitentan etiketi, İlaç etkileşimleri)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The concomitant use of METHADOSE with all cytochrome P450 3A4, 2B6, 2C19, 2C9 or 2D6 inhibitors may result in an increase in methadone plasma concentrations, which could cause potentially fatal respiratory depression. (Metadon etiketi, Kutulu uyarı)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Metamfetamin etiketi, İlaç etkileşimleri)

Although there have been no reports of such interactions with methylergonovine alone, strong and moderate CYP 3A4 inhibitors should not be co-administered with methylergonovine. (Metilergometrin etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors Monitor patients closely when the combination use of CYP2D6 inhibitor and metoprolol cannot be avoided. (Metoprolol etiketi, İlaç etkileşimleri)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (Everolimus etiketi, Uyarılar ve önlemler)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Patients concomitantly using strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) because these medications can significantly increase exposure to naloxegol which may precipitate opioid withdrawal symptoms such as hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning [see Drug Interactions (7.1) and Clinical Pharmacology… (Naloksegol etiketi, Kontrendikasyonlar)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Therefore, the concomitant administration of NYMALIZE and strong CYP3A4 inhibitors should generally be avoided [ see Warnings and Precautions (5.3) ]. (Nimodipin etiketi, İlaç etkileşimleri)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

CYP3A4 inhibitors and inducers : SULAR is substrate of CYP3A4 and coadministration of SULAR with any known inducer or inhibitor of CYP3A4 should be avoided in general. (Nisoldipin etiketi, İlaç etkileşimleri)

Cytochrome P450 3A4 Interaction The concomitant use of Oxycodone Hydrochloride Oral Solution with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (Oksikodon etiketi, Kutulu uyarı)

Cytochrome P450 3A4 Interaction The concomitant use of oxycodone hydrochloride tablets with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (Oksikodon ve parasetamol etiketi, Kutulu uyarı)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (Parasetamol ve kodein etiketi, Kutulu uyarı)

Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (Pazopanib etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Cytochrome P450 3A4 Interaction The concomitant use of DEMEROL Injection with all cytochrome P450 3A4 inhibitors may result in an increase in meperidine plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. (Petidin etiketi, Kutulu uyarı)

Concomitant use of pimozide with paroxetine and other strong CYP 2D6 inhibitors is contraindicated (See PRECAUTIONS – DRUG INTERACTIONS ). (Pimozid etiketi, Kontrendikasyonlar)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (Everolimus etiketi, Uyarılar ve önlemler)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. (Prometazin ve kodein etiketi, Kutulu uyarı)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

• Strong CYP3A4 Inhibitors: Avoid concomitant administration. (Rimegepant etiketi, İlaç etkileşimleri)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Use with P-gp and Strong CYP3A Inhibitors or Inducers Avoid concomitant use of XARELTO with known combined P-gp and strong CYP3A inhibitors [see Drug Interactions (7.2) ] . (Rivaroksaban etiketi, Uyarılar ve önlemler)

• Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. (Salmeterol etiketi, İlaç etkileşimleri)

Sarı kantaron, bu ilaçların yıkımını hızlandırarak onları zayıflatabilir; bu da organ reddi, pıhtı oluşumu veya etki kaybı anlamına gelebilir. (NCCIH, St. John's Wort)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Severe renal impairment (CCr < 30 mL/min) Severe hepatic impairment (Child-Pugh score ≥ 10) Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) [see DRUG INTERACTIONS (7.1) ] Patients with a history of hypersensitivity to silodosin or any of the ingredients in silodosin capsules… (Silodosin etiketi, Kontrendikasyonlar)

ZOCOR is contraindicated in the following conditions: Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) [see Drug Interactions (7.1) ] . (Simvastatin etiketi, Kontrendikasyonlar)

Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [ see Drug Interactions (7.2) ]. (Sirolimus etiketi, Uyarılar ve önlemler)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

The dosage of Solifenacin succinate tablets greater than 5 mg once daily is not recommended when concomitantly used with strong CYP3A4 inhibitors [see Dosage and Administration ( 2.4 )] . (Solifenasin etiketi, İlaç etkileşimleri)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ] . (Suzetrijin etiketi, Kontrendikasyonlar)

…IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (Takrolimus etiketi, Kutulu uyarı)

• Should not be used in combination with strong inhibitors of CYP3A4. (Tamsulosin etiketi, Uyarılar ve önlemler)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Avoid co-administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with TEPADINA due to the potential effects on efficacy and toxicity [see Clinical Pharmacology ( 12.3 ) ] . (Tiotepa etiketi, İlaç etkileşimleri)

…dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS [see Warnings and Precautions (5.2) ] Unable to sense or respond to thirst Hypovolemic hyponatremia Taking strong CYP3A inhibitors [see Warnings and Precautions (5.5) ] Anuria Hypersensitivity (e.g., anaphylactic shock, rash generalized) to tolvaptan or any components of the product [see Adverse… (Tolvaptan etiketi, Kontrendikasyonlar)

Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided [see Warnings and Precautions (5.1) ] . (Toremifen etiketi, Kutulu uyarı)

CYP3A inhibitors: Avoid concomitant strong CYP3A inhibitors ( 7.1 ) (Trabektedin etiketi, İlaç etkileşimleri)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (Tramadol etiketi, Kutulu uyarı)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (Tramadol ve parasetamol etiketi, Kutulu uyarı)

Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (Everolimus etiketi, İlaç etkileşimleri)

The use of RALDESY Should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic… (Trazodon etiketi, Uyarılar ve önlemler)

• Strong CYP3A Inhibitors and Inducers: Avoid coadministration with strong CYP3A inhibitors and inducers. (Tretinoin etiketi, İlaç etkileşimleri)

Strong CYP 3A Inhibitors Triazolam is contraindicated in patients receiving strong inhibitors of CYP 3A such as ketoconazole, itraconazole, nefazodone, ritonavir, indinavir, nelfinavir, saquinavir, and lopinavir [see Contraindications (4) , Drug Interactions (7.1) ] . (Triazolam etiketi, Uyarılar ve önlemler)

UBRELVY is contraindicated: With concomitant use of strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )] In patients with a history of serious hypersensitivity to ubrogepant or any component of UBRELVY. (Ubrogepant etiketi, Kontrendikasyonlar)

For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended. (Upadasitinib etiketi, İlaç etkileşimleri)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (Vepdegestrant etiketi, Uyarılar ve önlemler)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided. (Vinkristin etiketi, İlaç etkileşimleri)

Do not administer antifungal agents, unless fungal infection has been diagnosed. (Everolimus etiketi, Uyarılar ve önlemler)

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration. (Everolimus etiketi, İlaç etkileşimleri)

CYP3A4/5 Inhibitors Co-administration of ketoconazole, a strong inhibitor of CYP3A4/5, increased the plasma exposure of axitinib in healthy volunteers. (Aksitinib etiketi, İlaç etkileşimleri)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve atorvastatin etiketi, İlaç etkileşimleri)

• Increased exposure of amlodipine when coadministered with CYP3A inhibitors Olmesartan medoxomil ( 7.2 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS) may lead to increased risk of renal impairment and loss of antihypertensive effect. (Amlodipin ve olmesartan etiketi, İlaç etkileşimleri)

Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (Amlodipin ve valsartan etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors and CYP3A4 Inhibitors : See full prescribing information for ABILIFY MAINTENA dosage modifications when used concomitantly with CYP2D6 inhibitors and/or CYP3A4 inhibitors for greater than 14 days ( 7.1 ) (Aripiprazol etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Immunosuppressants: cyclosporine, sirolimus, tacrolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for these immunosuppressants when coadministered with REYATAZ. (Atazanavir etiketi, İlaç etkileşimleri)

Strong CYP2D6 Inhibitors Prevention or Management With concomitant use of atomoxetine oral solution and a strong CYP2D6 inhibitor 1 , increase the titration interval [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3) ] . (Atomoksetin etiketi, İlaç etkileşimleri)

LIPITOR plasma levels can be significantly increased with concomitant administration of inhibitors of CYP3A4 and transporters. (Atorvastatin etiketi, İlaç etkileşimleri)

Use of Cytochrome P450 3A4 Inhibitors Ritonavir and other strong cytochrome P450 3A4 (CYP3A4) inhibitors can significantly increase plasma fluticasone propionate exposure, resulting in significantly reduced serum cortisol concentrations [see Drug Interactions ( 7.2 ) and Clinical Pharmacology ( 12.3 )] . (Azelastin ve flutikazon etiketi, Uyarılar ve önlemler)

Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Bendamustin etiketi, Uyarılar ve önlemler)

Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

Strong CYP2D6 REXULTI may be administered without dosage adjustment in patients with MDD when administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine). or CYP3A4 inhibitors Administer half of recommended dosage. (Brekspiprazol etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)

Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to… (Budesonid etiketi, Uyarılar ve önlemler)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Budesonid ve formoterol etiketi, Uyarılar ve önlemler)

Inhibitors of CYP3A4 Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of buprenorphine and naloxone sublingual tablet is achieved. (Buprenorfin ve nalokson etiketi, İlaç etkileşimleri)

Other inhibitors and inducers of CYP3A4: Substances that inhibit CYP3A4, such as ketoconazole or ritonavir, may inhibit buspirone metabolism and increase plasma concentrations of buspirone while substances that induce CYP3A4, such as dexamethasone or certain anticonvulsants (phenytoin, phenobarbital, carbamazepine), may increase the rate of buspirone metabolism. (Buspiron etiketi, İlaç etkileşimleri)

Cannabidiol oral solution : Reduce the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

CYP3A4 Inhibitors The systemic exposure of darifenacin from darifenacin extended-release tablets is increased in the presence of CYP3A4 inhibitors. (Darifenasin etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of EMFLAZA ( 7.1 ) (Deflazakort etiketi, İlaç etkileşimleri)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of dexlansoprazole is expected when used concomitantly with strong inhibitors [see Clinical Pharmacology (12.3) ] . (Dekslansoprazol etiketi, İlaç etkileşimleri)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (Denosumab etiketi, Uyarılar ve önlemler)

CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. (Desogestrel ve etinilestradiol etiketi, İlaç etkileşimleri)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (Dofetilid etiketi, İlaç etkileşimleri)

Strong cytochrome P450 (CYP) 3A inhibitors may increase exposure to doxazosin and increased risk of hypotension. (Doksazosin etiketi, İlaç etkileşimleri)

Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. (Doravirin etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors may potentiate systemic beta-blockade. (Dorzolamid ve timolol etiketi, İlaç etkileşimleri)

Concomitant use of strong CYP2D6 inhibitors: Maximum recommended dose of AUSTEDO XR or AUSTEDO is 36 mg per day ( 2.3 , 7.1 ) (Dötetrabenazin etiketi, İlaç etkileşimleri)

Monitor for increased dronabinol-related adverse reactions when dronabinol oral solution is co-administered with inhibitors of CYP2C9 (e.g., amiodarone, fluconazole) and inhibitors of CYP3A4 enzymes (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit juice). (Dronabinol etiketi, İlaç etkileşimleri)

Consider monitoring serum potassium concentration in high-risk patients who take a strong CYP3A4 inhibitor long-term and concomitantly. (Drospirenon ve etinilestradiol etiketi, Uyarılar ve önlemler)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

When used concomitantly with digoxin or other substrates of P-gp with a narrow therapeutic index such as cyclosporine, everolimus, sirolimus and tacrolimus, caution and appropriate monitoring should be used [see Clinical Pharmacology (12.3) ] . (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Drugs Inducing or Inhibiting CYP3A Enzymes Rilpivirine is primarily metabolized by cytochrome P450 (CYP) 3A, and drugs that induce or inhibit CYP3A may thus affect the clearance of RPV [see Contraindications (4) , Warnings and Precautions (5.7) , and Clinical Pharmacology (12.3) ] . (Emtrisitabin, rilpivirin ve tenofovir etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects. (Estradiol etiketi, İlaç etkileşimleri)

…exposure at steady state. [See Clinical Pharmacology (12.3).] Substances Increasing the Systemic Exposure of COCs (enzyme inhibitors): Concomitant administration of moderate or strong CYP3A4 inhibitors like azole antifungals (for example, ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (for example, clarithromycin, erythromycin), diltiazem,… (Estradiol ve dienogest etiketi, İlaç etkileşimleri)

Inducers and/or inhibitors of CYP3A4 may affect estrogen drug metabolism and decrease or increase the estrogen plasma concentration. (Estradiol ve noretisteron etiketi, İlaç etkileşimleri)

The dose of LUNESTA should be reduced in patients who are administered potent inhibitors of CYP3A4, such as ketoconazole, while taking LUNESTA. (Eszopiklon etiketi, Uyarılar ve önlemler)

Concomitant administration of strong or moderate CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma estrogen and/or progestin concentrations. (Etonogestrel ve etinilestradiol etiketi, İlaç etkileşimleri)

Coadministration of CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several-fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism. (Felodipin etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (Fenofibrat etiketi, İlaç etkileşimleri)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (Fenofibrik asit etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Potential Pimozide Interaction Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. (Fluvoksamin etiketi, Uyarılar ve önlemler)

Antineoplastics: Dasatinib, nilotinib, ibrutinib, vinblastine, everolimus ↑Antineoplastics Fosamprenavir calcium or fosamprenavir calcium /ritonavir may increase plasma concentrations of antineoplastics metabolized by CYP3A, potentially increasing the risk of adverse events typically associated with these medications. (Fosamprenavir etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

• CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

Greyfurt suyu, nakil sonrası organ reddini önleyen ilaçların kan düzeylerini yükseltir. (FDA, Grapefruit Juice and Some Drugs Don't Mix)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

…Interactions: Effect of other Drugs on INTUNIV Concomitant Drug Name or Drug Class Clinical Rationale and Magnitude of Drug Interaction Clinical Recommendation Strong and moderate CYP3A4 inhibitors, e.g., ketoconazole, fluconazole Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in an increase… (Guanfasin etiketi, İlaç etkileşimleri)

The effect of CYP3A4 inhibition and of decreased CYP2D6 enzyme may be additive. (Haloperidol etiketi, İlaç etkileşimleri)

Concomitant administration of inhibitors of CYP3A4 may lead to increases in serum concentrations of ALKINDI SPRINKLE and increase the risk of adverse reactions associated with the use of excessive doses. (Hidrokortizon etiketi, İlaç etkileşimleri)

• CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (İfosfamid etiketi, İlaç etkileşimleri)

The dose of FANAPT should be reduced in patients co-administered a strong CYP2D6 or CYP3A4 inhibitor. (İloperidon etiketi, İlaç etkileşimleri)

When treating patients, consideration of whether to use RENFLEXIS alone or in combination with other immunosuppressants such as azathioprine or 6-mercaptopurine should take into account a possibility that there is a higher risk of HSTCL with combination therapy versus an observed increased risk of immunogenicity and hypersensitivity reactions with infliximab… (İnfliksimab etiketi, Uyarılar ve önlemler)

Cannabidiol oral solution : Reduce the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Clinically Significant Drug Interactions with VRAYLAR Strong or Moderate CYP3A4 Inhibitors Clinical Impact: Concomitant use of VRAYLAR with a strong or moderate CYP3A4 inhibitor increases the exposures of cariprazine and its major active metabolite, didesmethylcariprazine (DDCAR), compared to use of VRAYLAR alone [see Clinical Pharmacology ( 12.3 ) ]. (Kariprazin etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

• Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one‑sixth when coadministered with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) ( 2.5 , 7.1 , 12.3 ) (Ketiapin etiketi, İlaç etkileşimleri)

Although a causal relationship between a specific drug and the arrhythmia was not established in this case, erythromycin is a CYP3A4 inhibitor and has been shown to increase quinine plasma levels when used concomitantly. (Kinin etiketi, Uyarılar ve önlemler)

Inhibitors of CYP3A4 and CYP3A5 Inhibitors of CYP3A4 and/or CYP3A5 may increase plasma concentrations of clindamycin [ see Clinical Pharmacology (12.3) ]. (Klindamisin etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

CYP2D6 and CYP3A4 Inhibitors Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology ( 12.3 )] . (Klozapin etiketi, İlaç etkileşimleri)

Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone [see Pharmacokinetics (12.3) ] . (Konjuge östrojenler ve bazedoksifen etiketi, İlaç etkileşimleri)

Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to VIMPAT. (Lakozamid etiketi, İlaç etkileşimleri)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of lansoprazole is expected when used concomitantly with strong inhibitors [see Clinical Pharmacology (12.3) ] . (Lansoprazol etiketi, İlaç etkileşimleri)

If used with concomitant methotrexate and/or other potential immunosuppressive agents, chronic monitoring should be monthly. (Leflunomid etiketi, Uyarılar ve önlemler)

Strong CYP3A4 inhibitors : Maximum recommended dosage is 80 mg once daily ( 7 ). (Levomilnasipran etiketi, İlaç etkileşimleri)

CYP3A inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice The effect of grapefruit juice on CYP3A4 enzymes (e.g., strong vs. moderate inhibition) depends on its brand, concentration, and preparation. , or ketoconazole may increase systemic exposure of the estrogen and/or progestin component of CHCs. (Levonorgestrel ve etinilestradiol etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors : Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. (Lofeksidin etiketi, İlaç etkileşimleri)

Drug Interactions Effects of Other Drugs on Loperamide Concomitant use of loperamide hydrochloride capsules with inhibitors of CYP3A4 (e.g., itraconazole) or CYP2C8 (e.g., gemfibrozil) or inhibitors of P-glycoprotein (e.g., quinidine, ritonavir) can increase exposure to loperamide. (Loperamid etiketi, İlaç etkileşimleri)

Strong CYP3A4 inhibitors: Recommended dosage is 10.5 mg once daily. (Lumateperon etiketi, İlaç etkileşimleri)

Ketoconazole (Potent Inhibitor of CYP3A4) Coadministration of a single 500 mg oral dose of mefloquine with 400 mg of ketoconazole once daily for 10 days in 8 healthy volunteers resulted in an increase in the mean C max and AUC of mefloquine by 64% and 79%, respectively, and an increase in the mean elimination half-life of mefloquine from 322 hours to 448 hours. (Meflokin etiketi, İlaç etkileşimleri)

A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Merkaptopürin etiketi, Uyarılar ve önlemler)

• Strong CYP2D6 inhibitors (e.g., quinidine, bupropion, fluoxetine, and paroxetine) : See Full Prescribing Information for recommended dosage reductions. (Metoklopramid etiketi, İlaç etkileşimleri)

CYP2D6 inhibitors: Increased metoprolol concentration. (Metoprolol ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (Midazolam etiketi, İlaç etkileşimleri)

…mifepristone is contraindicated. [See Contraindications (4.3)] 5.6 Use of Strong CYP3A Inhibitors Mifepristone should be used with caution in patients taking ketoconazole and other strong inhibitors of CYP3A, such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir, fosamprenavir, clarithromycin, conivaptan, lopinavir/ritonavir, posaconazole,… (Mifepriston etiketi, Uyarılar ve önlemler)

Lymphoma and Other Malignancies Patients receiving immunosuppressants, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin [see Adverse Reactions ( 6.1 )]. (Mikofenolat etiketi, Uyarılar ve önlemler)

Examples phenytoin, carbamazepine, rifampin Strong CYP3A Inhibitors Clinical Impact The concomitant use of strong CYP3A inhibitors with REMERON/REMERONSolTab may increase the plasma concentration of mirtazapine [see Clinical Pharmacology (12.3) ] . (Mirtazapin etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (Mometazon etiketi, Uyarılar ve önlemler)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Naldemedin etiketi, İlaç etkileşimleri)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact : Increased exposure of esomeprazole [see Clinical Pharmacology (12.3) ]. (Naproksen ve esomeprazol etiketi, İlaç etkileşimleri)

Use with CYP2D6 Inhibitors Nebivolol exposure increases with inhibition of CYP2D6 [see Drug Interactions ( 7 ) ] . (Nebivolol etiketi, Uyarılar ve önlemler)

…Astemizole, Cisapride, and Pimozide Interactions Terfenadine, astemizole, cisapride, and pimozide are all metabolized by the cytochrome P450 3A4 (CYP3A4) isozyme, and it has been demonstrated that ketoconazole, erythromycin, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. (Nefazodon etiketi, Uyarılar)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

…as ketoconazole, fluconazole, itraconazole, clarithromycin, erythromycin (Azithromycin, although structurally related to the class of macrolide antibiotic is void of clinically relevant CYP3A4 inhibition), grapefruit, nefazodone, fluoxetine, saquinavir, indinavir, nelfinavir, and ritonavir may result in increased exposure to nifedipine when co-administered. (Nifedipin etiketi, İlaç etkileşimleri)

Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. (Nintedanib etiketi, İlaç etkileşimleri)

CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. (Norelgestromin ve etinilestradiol etiketi, İlaç etkileşimleri)

Substances increasing the systemic concentrations of HCs: Co-administration of certain HCs and strong or moderate CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase the systemic concentrations of progestins, including norethindrone. (Noretisteron etiketi, İlaç etkileşimleri)

CYP3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone levels. (Noretisteron ve etinilestradiol etiketi, İlaç etkileşimleri)

CYP3A4 inhibitors such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. (Norgestimat ve etinilestradiol etiketi, İlaç etkileşimleri)

Concomitant administration of CYP3A4 inhibitors such as itraconazole, fluconazole, grapefruit juice or ketoconazole may increase plasma hormone concentrations. (Norgestrel ve etinilestradiol etiketi, İlaç etkileşimleri)

Co-administration with strong cytochrome P450 (CYP) 3A4 inhibitors (e.g., ketoconazole) increases the systemic exposure of oxybutynin. (Oksibutinin etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Inhibitors of CYP2D6 Fluoxetine: Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. (Olanzapin etiketi, İlaç etkileşimleri)

The Effect of Other Drugs on Olanzapine — Fluoxetine, an inhibitor of CYP2D6, decreases olanzapine clearance a small amount [see Clinical Pharmacology ( 12.3 )]. (Olanzapin ve fluoksetin etiketi, İlaç etkileşimleri)

Risk of Use in Patients with Decreased Cytochrome P450 2D6 Function or Concomitant Use or Discontinuation with Cytochrome P450 3A4 Inhibitors and Inducers Risk of Increased Oliceridine Plasma Concentrations Increased plasma concentrations of oliceridine, which may result in prolonged opioid adverse reactions and exacerbated respiratory depression, may occur when… (Oliseridin etiketi, Uyarılar ve önlemler)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (Olmesartan, amlodipin ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

Concomitant administration of CYP3A4 inhibitors may inhibit the metabolism of, and increase the mometasone furoate plasma concentration and potentially increase the risk for adverse reactions. (Olopatadin ve mometazon etiketi, İlaç etkileşimleri)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of omeprazole [see Clinical Pharmacology ( 12.3 )] . (Omeprazol etiketi, İlaç etkileşimleri)

CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Increased exposure of omeprazole [see Clinical Pharmacology ( 12.3 )] . (Omeprazol ve sodyum bikarbonat etiketi, İlaç etkileşimleri)

The dose of the sensitive CYP3A substrate with a narrow therapeutic index (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) may need to be reduced, as IBRANCE may increase its exposure [see Clinical Pharmacology (12.3) ] . (Palbosiklib etiketi, İlaç etkileşimleri)

Exposure of Paricalcitol Injection will increase upon coadministration with strong CYP3A inhibitors [see Clinical Pharmacology (12.3) ] . (Parikalsitol etiketi, İlaç etkileşimleri)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (Penisilamin etiketi, Uyarılar)

Strong CYP3A4 Inhibitors: Reduce NUPLAZID dose to 10 mg once daily. (Pimavanserin etiketi, İlaç etkileşimleri)

Strong CYP2D6 Inhibitors: Increased exposure of WAKIX; reduce the maximum recommended dose of WAKIX by half ( 2.6 , 7.1 ) (Pitolisant etiketi, İlaç etkileşimleri)

CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (Prednizolon etiketi, İlaç etkileşimleri)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (Prednizon etiketi, İlaç etkileşimleri)

Effects of Other Drugs on the Pharmacokinetics of Primaquine Strong CYP2D6 Inhibitors Published clinical and non-clinical reports indicate reduced CYP2D6 activity may decrease the formation of active metabolites of primaquine, which may reduce antimalarial efficacy of Primaquine phosphate Tablets (see CLINICAL PHARMACOLOGY, Pharmacogenomics ). (Primakin etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Impact of Other Drugs on Propranolol CYP2D6, CYP1A2 and CYP2C19 Inhibitors: CYP2D6 inhibitors (e.g. bupropion, fluoxetine, paroxetine, quinidine), CYP1A2 inhibitors (e.g., ciprofloxacin, enoxamine, fluvoxamine) and CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) increase exposure to propranolol when co-administered with INNOPRAN XL. (Propranolol etiketi, İlaç etkileşimleri)

Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. (Ramelteon etiketi, İlaç etkileşimleri)

CYP2C8 and CYP3A4 Inhibitors Intervention: Repaglinide tablets dose reductions and increased frequency of glucose monitoring may be required when co‑administered. (Repaglinid etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Coadministration of EDURANT or EDURANT PED and drugs that inhibit CYP3A may result in increased plasma concentrations of rilpivirine. (Rilpivirin etiketi, İlaç etkileşimleri)

Fluoxetine and Paroxetine Fluoxetine (20 mg once daily) and paroxetine (20 mg once daily), CYP 2D6 inhibitors, have been shown to increase the plasma concentration of risperidone 2.5–2.8 fold and 3–9 fold respectively. (Risperidon etiketi, İlaç etkileşimleri)

Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine) will increase roflumilast systemic exposure and may result in increased adverse reactions. (Roflumilast etiketi, İlaç etkileşimleri)

• Monitor for toxicities related to increased romidepsin exposure when co-administering romidepsin with strong CYP3A4 inhibitors ( 7.2 ). (Romidepsin etiketi, İlaç etkileşimleri)

Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in vivo plasma clearance of ropivacaine. (Ropivakain etiketi, İlaç etkileşimleri)

Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

Strong Inhibitors of CYP3A4/5 Enzymes Ketoconazole significantly increased saxagliptin exposure. (Saksagliptin etiketi, İlaç etkileşimleri)

Strong Inhibitors of CYP3A4/5 Enzymes Ketoconazole significantly increased saxagliptin exposure. (Saksagliptin ve metformin etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

In a drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged. (Siklesonid etiketi, İlaç etkileşimleri)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (Sildenafil etiketi, İlaç etkileşimleri)

Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4 Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol. (Silostazol etiketi, İlaç etkileşimleri)

Co-administration with a strong CYP3A4 inhibitor may increase serum levels of cinacalcet. (Sinakalset etiketi, İlaç etkileşimleri)

Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (Sunitinib etiketi, Uyarılar ve önlemler)

…Physicians should be aware that CIALIS for once daily use provides continuous plasma tadalafil levels and should consider this when evaluating the potential for interactions with medications (e.g., nitrates, alpha-blockers, anti-hypertensives and potent inhibitors of CYP3A4) and with substantial consumption of alcohol [see Drug Interactions ( 7.1 , 7.2 , 7.3 )] . (Tadalafil etiketi, Uyarılar ve önlemler)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Telmisartan ve amlodipin etiketi, İlaç etkileşimleri)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Temsirolimus etiketi, Uyarılar ve önlemler)

• Do not exceed 50 mg/day and the maximum single dose should not exceed 25 mg if administered in conjunction with a strong CYP2D6 inhibitor (e.g., fluoxetine, paroxetine). (Tetrabenazin etiketi, Uyarılar ve önlemler)

CYP2D6 Inhibitors Potentiated systemic beta-blockade (e.g., decreased heart rate) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine) and timolol. (Timolol etiketi, İlaç etkileşimleri)

Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (Tinidazol etiketi, İlaç etkileşimleri)

Table 7: Clinically Significant Interactions Affecting XELJANZ/XELJANZ XR When Concomitantly Used with Other Drugs Strong CYP3A4 Inhibitors (e.g., ketoconazole) Clinical Impact Increased exposure to tofacitinib Intervention Dosage modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2) , Clinical Pharmacology, Figure 3 (12.3) ] Moderate… (Tofasitinib etiketi, İlaç etkileşimleri)

Drug Interactions CYP3A4 Inhibitors Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions ). (Tolterodin etiketi, İlaç etkileşimleri)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (Everolimus etiketi, İlaç etkileşimleri)

Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with KENALOG-40 Injection may cause increased plasma concentration of triamcinolone leading to adverse reactions. (Triamsinolon etiketi, İlaç etkileşimleri)

Increase in Plasma Concentrations of ella Associated with Co-Administered Drugs CYP3A4 inhibitors such as itraconazole or ketoconazole increase plasma concentrations of ella [see Pharmacokinetics (12.3) ] . (Ulipristal etiketi, İlaç etkileşimleri)

Drug Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of Umeclidinium and Vilanterol ELLIPTA with ketoconazole and other known strong cytochrome P450 3A4 (CYP3A4) inhibitors (including, but not limited to, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone,… (Umeklidinyum ve vilanterol etiketi, Uyarılar ve önlemler)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (Valbenazin etiketi, Uyarılar ve önlemler)

Potential for Drug Interactions with Strong or Moderate CYP3A4 Inhibitors Concomitant administration with strong CYP3A4 inhibitors (such as ritonavir, indinavir, cobicistat, ketoconazole) or moderate CYP3A4 inhibitors (such as erythromycin) increases plasma concentrations of vardenafil. (Vardenafil etiketi, Uyarılar ve önlemler)

Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer. (Varfarin etiketi, İlaç etkileşimleri)

Therefore, the potential exists for a drug interaction between drugs that inhibit CYP2D6-mediated metabolism of venlafaxine, reducing the metabolism of venlafaxine to ODV, resulting in increased plasma concentrations of venlafaxine and decreased concentrations of the active metabolite. (Venlafaksin etiketi, İlaç etkileşimleri)

CYP3A4 Inhibitors: The VIIBRYD dose should not exceed 20 mg once daily when co-administered with strong CYP3A4 inhibitors ( 2.4 , 7 ). (Vilazodon etiketi, İlaç etkileşimleri)

CYP2D6 Substrates Clinical Impact Viloxazine is a weak inhibitor of CYP2D6, and increases the exposure of CYP2D6 substrates when coadministered [see Clinical Pharmacology (12.3) ] . (Viloksazin etiketi, İlaç etkileşimleri)

Inhibitors of CYP3A4: May cause earlier onset and/or increased severity of adverse reactions ( 7.1 ) (Vinorelbin etiketi, İlaç etkileşimleri)

• Strong inhibitors of CYP2D6: Reduce TRINTELLIX dose by half when coadministered ( 2.5 , 7.1 ). (Vortioksetin etiketi, İlaç etkileşimleri)

As zafirlukast is known to be an inhibitor of CYP3A4 in vitro , it is reasonable to employ appropriate clinical monitoring when these drugs are coadministered with zafirlukast. (Zafirlukast etiketi, Önlemler)

Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. (Zaleplon etiketi, İlaç etkileşimleri)

Ketoconazole Ketoconazole, a potent inhibitor of CYP3A4, at a dose of 400 mg QD for 5 days, increased the AUC and C max of ziprasidone by about 35 to 40%. (Ziprasidon etiketi, İlaç etkileşimleri)

CYP3A4 Inhibitors Ketoconazole Ketoconazole, a potent CYP3A4 inhibitor, increased the exposure to and pharmacodynamic effects of zolpidem. (Zolpidem etiketi, İlaç etkileşimleri)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Corticosteroids may be indicated until clinical symptoms resolve. (Everolimus etiketi, Uyarılar ve önlemler)

Corticosteroids may be indicated until clinical symptoms resolve. (Everolimus etiketi, Uyarılar ve önlemler)

Corticosteroids may be indicated until clinical symptoms resolve. (Everolimus etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Although potent inhibitors of cytochrome P450 3A4 (e.g., ketoconazole) have not been studied clinically, in vitro studies have shown that erythromycin and oleandomycin inhibit the metabolism of disopyramide. (Disopiramid etiketi, İlaç etkileşimleri)

The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (Dutasterid etiketi, İlaç etkileşimleri)

TAF is a weak inhibitor of CYP3A in vitro . (Emtrisitabin ve tenofovir etiketi, İlaç etkileşimleri)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (Eribulin etiketi, İlaç etkileşimleri)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

An in vitro study using human liver microsomes suggests that famciclovir is not an inhibitor of CYP3A4 enzymes. (Famsiklovir etiketi, İlaç etkileşimleri)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Additionally, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than fluoxetine or norfluoxetine as an inhibitor of the metabolism of several substrates for this enzyme, including astemizole, cisapride, and midazolam. (Fluoksetin etiketi, İlaç etkileşimleri)

Corticosteroids may be indicated until clinical symptoms resolve. (Everolimus etiketi, Uyarılar ve önlemler)

IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (Fluvastatin etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Corticosteroids may be indicated until clinical symptoms resolve. (Everolimus etiketi, Uyarılar ve önlemler)

Corticosteroids may be indicated until clinical symptoms resolve. (Everolimus etiketi, Uyarılar ve önlemler)

The selective serotonin reuptake inhibitors sertraline (weak CYP3A4 inducer) and fluoxetine (CYP2D6 inhibitor), and the anti-epileptic drug felbamate (CYP2C19 inhibitor and CYP3A4 inducer) do not affect the pharmacokinetics of clonazepam. (Klonazepam etiketi, İlaç etkileşimleri)

Effect of SUNLENCA on Other Drugs Lenacapavir is a moderate inhibitor of CYP3A. (Lenakapavir etiketi, İlaç etkileşimleri)

• CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a potential for drug-drug interactions between meclizine hydrochloride and CYP2D6 inhibitors ( 7.2 ). (Meklizin etiketi, İlaç etkileşimleri)

Effect of Other Drugs on the Metabolism of Donepezil Inhibitors of CYP3A4 (e.g., ketoconazole) and CYP2D6 (e.g., quinidine), inhibit donepezil metabolism in vitro . (Memantin ve donepezil etiketi, İlaç etkileşimleri)

Corticosteroids may be indicated until clinical symptoms resolve. (Everolimus etiketi, Uyarılar ve önlemler)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Metimazol etiketi, Uyarılar)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Pitavastatin etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Pravastatin etiketi, Uyarılar ve önlemler)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Propiltiourasil etiketi, Uyarılar)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Rosuvastatin etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

CYP2D6 substrates Clinical Impact: In vitro studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. (Selekoksib etiketi, İlaç etkileşimleri)

Drugs Metabolized by CYP2D6 Clinical Impact: Sertraline hydrochloride capsules are a CYP2D6 inhibitor [see Clinical Pharmacology ( 12.3 )] . (Sertralin etiketi, İlaç etkileşimleri)

Drugs which inhibit CYP2D6 and CYP3A3/4 also inhibit the metabolism of cevimeline. (Sevimelin etiketi, İlaç etkileşimleri)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (Tamoksifen etiketi, İlaç etkileşimleri)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

Administer prophylaxis for PJP when concomitant use of corticosteroids or other immunosuppressive agents are required. (Everolimus etiketi, Uyarılar ve önlemler)

However, no formal drug-drug interaction studies between zileuton and CYP3A4 inhibitors, such as ketaconazole, have been conducted. (Zileuton etiketi, İlaç etkileşimleri)

Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (Desloratadin etiketi, İlaç etkileşimleri)